Literature DB >> 6431906

Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives.

N Eguchi, Y Watanabe, K Kawanishi, Y Hashimoto, O Hayaishi.   

Abstract

beta-Carboline derivatives inhibited both indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase activities from various sources. Among them, norharman is most potent for both enzymes from mammalian sources. Kinetic studies revealed that norharman is uncompetitive (Ki = 0.12 mM) with L-tryptophan for rabbit intestinal indoleamine 2,3-dioxygenase, and linearly competitive (Ki = 0.29 mM) with L-tryptophan for mouse liver tryptophan 2,3-dioxygenase. In addition, some beta-carbolines selectively inhibited one enzyme or the other. Pseudomonad tryptophan 2,3-dioxygenase was inhibited by a different spectrum of beta-carbolines. Such a selective inhibition by the structure of substrate analogs is more evident by the use of indole derivatives. Indole-3-acetamide, indole-3-acetonitrile and indole-3-acrylic acid exhibited a potent inhibition for mammalian tryptophan 2,3-dioxygenase, while they moderately inhibited the pseudomonad enzyme. However, they showed no inhibition for indoleamine 2,3-dioxygenase. These results suggest the difference of the structures of the active sites among these enzymes from various sources.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431906     DOI: 10.1016/0003-9861(84)90579-4

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  15 in total

1.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Authors:  Luc Pilotte; Pierre Larrieu; Vincent Stroobant; Didier Colau; Eduard Dolusic; Raphaël Frédérick; Etienne De Plaen; Catherine Uyttenhove; Johan Wouters; Bernard Masereel; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor.

Authors:  Benjamin J Moyer; Itzel Y Rojas; Iain A Murray; Seokwon Lee; Haley F Hazlett; Gary H Perdew; Craig R Tomlinson
Journal:  Toxicol Appl Pharmacol       Date:  2017-03-20       Impact factor: 4.219

Review 3.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 4.  Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases.

Authors:  Charlotte Teunis; Max Nieuwdorp; Nordin Hanssen
Journal:  Metabolites       Date:  2022-06-02

5.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Authors:  Sanjeev Kumar; Daniel Jaller; Bhumika Patel; Judith M LaLonde; James B DuHadaway; William P Malachowski; George C Prendergast; Alexander J Muller
Journal:  J Med Chem       Date:  2008-07-30       Impact factor: 7.446

6.  Antibiotic-mediated release of tumour necrosis factor alpha and norharman in patients with hospital-acquired pneumonia and septic encephalopathy.

Authors:  Verena Eggers; Katja Fügener; Ortrud Vargas Hein; Hans Rommelspacher; Melvyn P Heyes; Wolfgang J Kox; Claudia D Spies
Journal:  Intensive Care Med       Date:  2004-04-27       Impact factor: 17.440

7.  4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells).

Authors:  K Saito; C Y Chen; M Masana; J S Crowley; S P Markey; M P Heyes
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

8.  Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Authors:  Sanjeev Kumar; William P Malachowski; James B DuHadaway; Judith M LaLonde; Patrick J Carroll; Daniel Jaller; Richard Metz; George C Prendergast; Alexander J Muller
Journal:  J Med Chem       Date:  2008-03-05       Impact factor: 7.446

Review 9.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

Review 10.  TDO as a therapeutic target in brain diseases.

Authors:  Cheng-Peng Yu; Ze-Zheng Pan; Da-Ya Luo
Journal:  Metab Brain Dis       Date:  2016-04-13       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.